BMS 986189

Drug Profile

BMS 986189

Alternative Names: BMS-986189; BMS-986189-07

Latest Information Update: 19 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Sepsis

Most Recent Events

  • 14 Apr 2016 Bristol-Myers Squibb plans a phase I pharmacokinetics trial in Healthy volunteers in USA (unspecified) (NCT02739373)
  • 08 Apr 2016 Preclinical trials in Sepsis in USA (unspecified route) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top